{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:13:47Z","timestamp":1772450027509,"version":"3.50.1"},"reference-count":51,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Serum neurofilament light chain (sNfL) is a biomarker for peripheral neuropathy as sNfL correlates with polyneuropathy severity in hereditary transthyretin (ATTRv) amyloidosis. It is unclear whether sNfL also correlates with autonomic neuropathy (ANP). In this exploratory study, we aimed to evaluate the value of sNfL as marker for ANP in patients with ATTRv amyloidosis. Methods: sNfL was measured retrospectively in 10 pathogenic transthyretin gene variant (TTRv) carriers and 28 patients with ATTRv amyloidosis. All 38 individuals underwent a comprehensive evaluation for ANP. Results: Individuals with ANP had a higher median sNfL level compared to those without ANP (p &lt; 0.001). In univariable logistic regression analysis, age-adjusted sNfL status (normal versus abnormal for age) was associated with sex, ANP, and peripheral neuropathy. In multivariable logistic regression analysis, only peripheral neuropathy significantly predicted age-adjusted sNfL status (normal versus abnormal for age), and no signal was detected for ANP. Receiver operating characteristic analysis showed a considerable area under the curve for ANP. However, the confidence interval was wide for both analyses and only four cases with isolated ANP were included. Conclusions: Therefore, in this exploratory cohort, sNfL could not be identified as a marker for ANP, and larger studies are needed to clarify its value.<\/jats:p>","DOI":"10.3390\/jcm15051862","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:24:34Z","timestamp":1772447074000},"page":"1862","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploratory Evaluation of the Predictive Value of Serum Neurofilament Light Chain for Autonomic Neuropathy in Hereditary Transthyretin Amyloidosis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1056-0482","authenticated-orcid":false,"given":"Milou","family":"Berends","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Amyloidosis Center of Expertise, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Floor","family":"Brunger","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, Martini Hospital, 9728 NT Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrea S. A.","family":"Tingen","sequence":"additional","affiliation":[{"name":"Amyloidosis Center of Expertise, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-4460","authenticated-orcid":false,"given":"Johan","family":"Bijzet","sequence":"additional","affiliation":[{"name":"Amyloidosis Center of Expertise, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Department of Laboratory Medicine, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A. van der","family":"Zwaag","sequence":"additional","affiliation":[{"name":"Amyloidosis Center of Expertise, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Department of Genetics, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-2387","authenticated-orcid":false,"given":"Reinold O. B.","family":"Gans","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Amyloidosis Center of Expertise, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouke P. C.","family":"Hazenberg","sequence":"additional","affiliation":[{"name":"Amyloidosis Center of Expertise, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Department of Rheumatology & Clinical Immunology, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4840-8799","authenticated-orcid":false,"given":"Fiete","family":"Lange","sequence":"additional","affiliation":[{"name":"Amyloidosis Center of Expertise, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Department of Neurology, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3546-4548","authenticated-orcid":false,"given":"Gea","family":"Drost","sequence":"additional","affiliation":[{"name":"Amyloidosis Center of Expertise, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Department of Neurology, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6386-5499","authenticated-orcid":false,"given":"Walter","family":"Noordzij","sequence":"additional","affiliation":[{"name":"Amyloidosis Center of Expertise, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3974-6830","authenticated-orcid":false,"given":"Hans L. A.","family":"Nienhuis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Amyloidosis Center of Expertise, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-1164","authenticated-orcid":false,"given":"Riemer H. J. A.","family":"Slart","sequence":"additional","affiliation":[{"name":"Amyloidosis Center of Expertise, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Biomedical Photonic Imaging Group, Faculty of Science and Technology, University of Twente, 7522 NB Enschede, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mus.20821","article-title":"The molecular biology and clinical features of amyloid neuropathy","volume":"36","author":"Benson","year":"2007","journal-title":"Muscle Nerve"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: Clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: Improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/13506129.2022.2065191","article-title":"Hereditary transthyretin amyloidosis in Sweden: Comparisons between a non-endemic and an endemic region","volume":"29","author":"Samuelsson","year":"2022","journal-title":"Amyloid"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105313","DOI":"10.1016\/j.neuint.2022.105313","article-title":"Transthyretin: Its function and amyloid formation","volume":"155","author":"Ueda","year":"2022","journal-title":"Neurochem. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"Red-flag symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Obici","year":"2016","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"oead106","DOI":"10.1093\/ehjopen\/oead106","article-title":"Cardiac amyloidosis and aortic stenosis: A state-of-the-art review","volume":"3","author":"Jaiswal","year":"2023","journal-title":"Eur. Heart J. Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ana.24725","article-title":"Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: An answer to the paradox?","volume":"80","author":"Loavenbruck","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3109\/13506129809007303","article-title":"Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP)","volume":"5","author":"Ando","year":"1998","journal-title":"Amyloid"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: A model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","article-title":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis","volume":"29","author":"Obici","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First european consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy","volume":"29","author":"Adams","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3389\/fneur.2019.00970","article-title":"Architecture of the Cutaneous Autonomic Nervous System","volume":"10","author":"Glatte","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Berends, M., Nienhuis, H.L.A., Adams, D., Karam, C., Luigetti, M., Polydefkis, M., Reilly, M.M., Sekijima, Y., and Hazenberg, B.P.C. (2024). Neurofilament Light Chains in Systemic Amyloidosis: A Systematic Review. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202402.1673.v1"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.artmed.2013.04.007","article-title":"An approach for Ewing test selection to support the clinical assessment of cardiac autonomic neuropathy","volume":"58","author":"Stranieri","year":"2013","journal-title":"Artif. Intell. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/bmj.285.6346.916","article-title":"Diagnosis and management of diabetic autonomic neuropathy","volume":"285","author":"Ewing","year":"1982","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12350-017-1059-9","article-title":"Imaging cardiac innervation in amyloidosis","volume":"26","author":"Slart","year":"2019","journal-title":"J. Nucl. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/13506129.2020.1769059","article-title":"Cardiac sympathetic denervation in wild-type transthyretin amyloidosis","volume":"27","author":"Gimelli","year":"2020","journal-title":"Amyloid"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s002590050406","article-title":"Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability","volume":"26","author":"Delahaye","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1007\/s12350-018-01477-y","article-title":"Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?","volume":"27","author":"Jonker","year":"2020","journal-title":"J. Nucl. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2337\/dc10-1303","article-title":"Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments","volume":"33","author":"Tesfaye","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00259-012-2187-8","article-title":"123I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis","volume":"39","author":"Noordzij","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0735-1097(96)00438-X","article-title":"Iodine-123 Metaiodobenzylguanidine Scintigraphic Assessment of Myocardial Sympathetic Innervation in Patients With Familial Amyloid Polyneuropathy","volume":"29","author":"Tanaka","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0002-9440(10)63050-7","article-title":"Deposition of Transthyretin in Early Stages of Familial Amyloidotic Polyneuropathy Evidence for Toxicity of Nonfibrillar Aggregates","volume":"159","author":"Cardoso","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s12350-016-0546-8","article-title":"Correction of collimator-dependent differences in the heart-to-mediastinum ratio in 123I-metaiodobenzylguanidine cardiac sympathetic imaging: Determination of conversion equations using point-source imaging","volume":"24","author":"Inoue","year":"2017","journal-title":"J. Nucl. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-010-1491-4","article-title":"Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology","volume":"37","author":"Flotats","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s12350-014-9916-2","article-title":"Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations","volume":"21","author":"Nakajima","year":"2014","journal-title":"J. Nucl. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mayocp.2012.10.013","article-title":"COMPASS 31: A refined and abbreviated composite autonomic symptom score","volume":"87","author":"Sletten","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.50.5.1213","article-title":"Limitations of quantitative sensory testing when patients are biased toward a bad outcome","volume":"50","author":"Dyck","year":"1998","journal-title":"Neurology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1212\/WNL.49.1.229","article-title":"Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort","volume":"49","author":"Dyck","year":"1997","journal-title":"Neurology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1515\/cclm-2022-0007","article-title":"Pre-analytical stability of serum biomarkers for neurological disease: Neurofilament-light, glial fibrillary acidic protein and contactin-1","volume":"60","author":"Verberk","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/acn3.51676","article-title":"Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface","volume":"9","author":"Vermunt","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s10072-021-05850-7","article-title":"Neurofilament light chain as a disease severity biomarker in ATTRv: Data from a single-centre experience","volume":"43","author":"Luigetti","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1007\/s10072-025-08110-0","article-title":"NfL as a biomarker in ATTRv amyloidosis: Potential and limitations","volume":"46","author":"Russo","year":"2025","journal-title":"Neurol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/jns.12575","article-title":"Plasma neurofilament light chain concentrations are elevated in youth-onset type 2 diabetes and associated with neuropathy","volume":"28","author":"Fridman","year":"2023","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1007\/s10072-024-07562-0","article-title":"Serum neurofilament light chain levels correlate with small fiber related parameters in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN)","volume":"45","author":"Galosi","year":"2024","journal-title":"Neurol. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/ene.15268","article-title":"Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis","volume":"29","author":"Leonardi","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ana.24972","article-title":"Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy","volume":"82","author":"Ebenezer","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.25433","article-title":"Skin nerve pathology: Biomarkers of premanifest and manifest amyloid neuropathy","volume":"85","author":"Chao","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e16192","DOI":"10.1111\/ene.16192","article-title":"Studying serum neurofilament light chain levels as a potential new biomarker for small fiber neuropathy","volume":"31","author":"Baka","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/13506129.2022.2070470","article-title":"A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"29","author":"Coelho","year":"2022","journal-title":"Amyloid"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/13506129.2024.2327342","article-title":"Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis","volume":"31","author":"Berends","year":"2024","journal-title":"Amyloid"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/13506129.2024.2313218","article-title":"Serum neurofilament light chain in hereditary transthyretin amyloidosis: Validation in real-life practice","volume":"31","author":"Carroll","year":"2024","journal-title":"Amyloid"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00415-025-13072-6","article-title":"Elevated serum concentrations of GFAP in hereditary transthyretin amyloidosis since pre-symptomatic stages","volume":"272","author":"Plantone","year":"2025","journal-title":"J. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13506129.2019.1582023","article-title":"Cardiac and peripheral vasomotor autonomic functions in hereditary transthyretin amyloidosis with non-Val30Met mutation","volume":"26","author":"Koike","year":"2019","journal-title":"Amyloid"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/CIRCIMAGING.112.000367","article-title":"Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: A prognostic marker in familial amyloid polyneuropathy","volume":"6","author":"Coutinho","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.clinph.2016.02.013","article-title":"The diagnostic accuracy of sudoscan in transthyretin familial amyloid polyneuropathy","volume":"127","author":"Castro","year":"2016","journal-title":"Clin. Neurophysiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/1862\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:50:18Z","timestamp":1772448618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/1862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15051862"],"URL":"https:\/\/doi.org\/10.3390\/jcm15051862","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}